Global Anemia Therapeutics Market 2017-2021
About Anemia Therapeutics
It is a medical condition that is characterized by the decrease in RBC count. RBCs make up the blood, and its main function is to deliver oxygen from lungs to other tissues and carbon dioxide from other tissues back to the lungs. This function is accomplished by hemoglobin, an iron-containing biomolecule present at the cytoplasm of an RBC and can efficiently bind to oxygen. In anemia, the decreased RBC count results in the impairment of the body's ability for gas exchange (oxygen and carbon dioxide). This decrease may result from hemolysis (destruction of RBC), hemorrhage (blood loss), or decreased production of RBCs.
Technavio’s analysts forecast the global anemia therapeutics market to grow at a CAGR of 8.55% during the period 2017-2021 .
Covered in this report
The report covers the present scenario and the growth prospects of the global anemia therapeutics market for 2017-2021 . To calculate the market size, the report considers the sales of branded, generic, and off-label drugs used for the treatment of anemia.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Anemia Therapeutics Market 2017-2021
Technavio recognizes the following companies as the key players in the global anemia therapeutics market: AMAG Pharmaceuticals, Daiichi Sankyo, Galenica, and Pharmacosmos
Other Prominent Vendors in the market are: Acceleron Pharma, Bayer, GlycoMimetics, GlaxoSmithKline, Novartis, Pieris Pharmaceuticals, and Sanofi.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is Growing focus on emerging economies. The growing focus of vendors on emerging economies will create growth opportunities. The emerging countries such as China, India, and Brazil are witnessing an increased prevalence of CKD and other diseases such as congestive heart failure. This has driven vendors to focus on emerging economies, which will enable them to expand their sources of revenue.”
According to the report, one of the major drivers for this market is Presence of large patient pool with various disorders. Intravenous anemia therapeutics have increased in demand owing to the presence of large patient pools globally. Some of the risk factors that lead to anemia include CKD, non-dialysis CKD, congestive heart failure, chemotherapy-induced anemia, inflammatory bowel syndrome, surgeries, heavy uterine bleeding, and postpartum depression. As per the NIH, an estimated 200 million globally, were suffering from CKD in 2014, with low to middle income countries leading the chart. Most of the deaths related to the kidney occur in developing countries largely due to expensive treatment and inappropriate healthcare infrastructure.
Further, the report states that one of the major factors hindering the growth of this market is High cost of drugs. The high cost of drugs associated with the use of anemia therapeutics, particularly the intravenous iron drugs used for the treatment of iron deficiency anemia, may pose a challenge to the market. There are many benefits of intravenous iron drugs over oral iron drugs. However, intravenous iron drugs are costlier than oral iron drugs. This may hinder the adoption rates of intravenous iron drugs and may drive end-users to choose low-cost alternatives.
AMAG Pharmaceuticals, Daiichi Sankyo, Galenica, Pharmacosmos, Acceleron Pharma, Bayer, GlycoMimetics, GlaxoSmithKline, Novartis, Pieris Pharmaceuticals, and Sanofi.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook